pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,337 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1891Endpoints1465Fierce Biotech779BioSpace767BioPharma Dive555raps254onclive165fda recalls
therapy area
allOncology13094Rare Disease3387Immunology3069Cardiology2866Hematology2335Pulmonology2299Vaccines
  • AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeutics
    AbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
    Fierce Biotech · 2d agoDealPositive↗ source
  • Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension study
    Biogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…
    Fierce Biotech · 2d agoPositive readoutPositive↗ source
← prev
page 2 of 54
next →
125
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signal
    German biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…
    Fierce Biotech · 2d agoNegative readoutNegative↗ source
  • Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s Patients
    Cognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
    Fierce Biotech · 2d agoNegative readoutNeutral↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 2d agoApprovalPositive↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 2d agoNegative readoutNegative↗ source
  • Big Pharma execs urge biotech firms to be transparent and patient to win deals
    At Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…
    Fierce Biotech · 2d agoDealNeutral↗ source
  • Crown Biosciences remains independent after $204 million Adicon acquisition collapses
    Crown Biosciences, a contract research organization, will continue operating on its own after a planned sale to China's Adicon did not close. The parties announced on Nov 16 that they were ending…
    Fierce Biotech · 2d agoDealNegative↗ source
  • Quanterix CEO Everett Cunningham resigns after ten months, interim leader appointed
    Quanterix announced that Everett Cunningham will leave his role as president and chief executive officer after serving less than a year. The company said he will step down to pursue another opportu…
    Fierce Biotech · 2d agoNeutral↗ source
  • FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
    FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
    fda press · 3d agoApprovalPositive↗ source
  • Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raise
    Isomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugs
    Eli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
    Fierce Biotech · 3d agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA nomination hours before Senate vote
    The White House has reportedly withdrawn the nomination of Dr. Heidi Overton, who was slated to become the FDA’s next commissioner, just hours before the Senate HELP Committee was set to vote. Ove…
    Fierce Biotech · 3d agoRegulatoryNegative↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 3d agoCRLNegative↗ source
  • FDA unveils Global Reliance Disclosure Program to speed international drug approvals
    The FDA announced the Global Reliance Disclosure Program (GRDP) on November 17, 2026, describing it as a new effort to share its drug and biologic approval packages with other health authorities.…
    fda press · 3d agoRegulatoryPositive↗ source
  • Vertex renews partnership with Genomics in up to $220 million, four-year extension
    Vertex Pharmaceuticals has extended its collaboration with sequencing specialist Genomics, signing a new agreement that can be worth up to $220 million. The extension adds four more years to the e…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Mount Sinai researchers map enzyme structure linked to rare metabolic disorder GA1
    Researchers at Icahn School of Medicine at Mount Sinai have determined the crystal structure of an upstream enzyme involved in glutaric aciduria type 1 (GA1), a rare neuro‑metabolic disease. GA1 r…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source
  • Medtronic to acquire Contego Medical for over $380 million to expand carotid and peripheral vascular portfolio
    Medtronic announced it will purchase Contego Medical, a developer of carotid artery disease and peripheral thrombectomy technologies. The deal is valued at more than $380 million, with potential a…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Kyntra Bio drops mid-stage prostate cancer ADC program after failing efficacy criteria
    Kyntra Bio announced in its third-quarter earnings release that it is terminating the phase 2 study of its CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate…
    Fierce Biotech · 3d agoNegative↗ source
  • Panelists say 2027 could be Europe’s breakout year for biotech investment
    Fierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…
    Fierce Biotech · 3d agoPositive↗ source
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 3d agoCRLNegative↗ source
  • EU regulators and industry discuss streamlining combination product oversight at summit
    At the AFDO/RAPS Combination Products Summit, a panel of European regulators and industry representatives met to explore ways to simplify the regulatory pathway for combination products in the EU.…
    raps · 3d agoRegulatoryNeutral↗ source
  • FDA releases new manual outlining clinical pharmacology review practices for NDAs and BLAs
    The U.S. Food and Drug Administration’s Office of Translational Sciences and Office of Clinical Pharmacology have issued a new manual of procedures and policies (MAPP).\n\nThe document sets out goo…
    raps · 3d agoRegulatoryNeutral↗ source
  • Larbi Inc. recalls three lots of Yellow Dock Root over possible Salmonella contamination
    Larbi Inc. announced a recall of three lots of its Herb To Body Yellow Dock Root 4-oz product because it may be contaminated with Salmonella. The product was sold nationwide from January to Novemb…
    fda recalls · 2d agoCRLNegative↗ source
  • React Health issues voluntary recall of Luna G3 BPAP devices over data handling error
    React Health (operating as 3B Medical) announced a voluntary correction of certain Luna G3 BPAP System units (model LG3800-30VT) because a data handling issue can produce incorrect therapy pressure…
    fda recalls · 3d agoRegulatoryNegative↗ source